Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Issue 8 (3rd July 2019)

• Record Type: Journal Article
• Authors: Roswarski, Joseph; Roschewski, Mark; Melani, Christopher; Pittaluga, Stefania; Lucas, Andrea; Steinberg, Seth M.; Jaffe, Elaine S.; Waldmann, Thomas A.; Wilson, Wyndham H.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 8(2019)
• Page Start: 2062
• Page End: 2066
• Publication Date: 2019-07-03
• Subjects: EPOCH -- alemtuzumab -- lymphoma -- PTCL; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1562184
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: To evaluate the feasibility and clinical efficacy of the combination of alemtuzumab with dose-adjusted etoposide/cyclophosphamide/doxorubicin/vincristine/prednisone (DA-EPOCH) as upfront therapy for untreated aggressive T and NK cell lymphomas, a phase 1/2 trial was conducted. Thirty patients were treated with the study regimen, consisting of alemtuzumab on day 1 of a 21 day cycle with standard dosing of DA-EPOCH for 6–8 cycles. Alemtuzumab 30 mg IV was used for the phase 2 component. Of 30 treated patients, 17 had a complete response (CR) and eight had a partial response (83.3% overall response rate). The median overall survival and progression-free survival were 20.2 and 6.6 months, respectively. There were five treatment-related deaths on study mainly due to infectious complications, including one case each of disseminated toxoplasmosis and pneumonia and two cases of sepsis. Alemtuzumab with DA-EPOCH is of limited clinical utility due to unacceptable toxicity, despite the high rate of CR.